Biotech and pharmaceutical companies have made a huge push to move off paper notebooks over the past two decades. However, legacy ELNs and LIMS are difficult to update, silo data, and limit collaboration, slowing progress and hindering an organization's ability to leverage insights, automation, and AI/ML. While many of these platforms claim to be modern and integrated, their product and user experience often fall short. The lack of an adaptable and modern underlying platform - not built with the complexity of biologics in mind - means that they fail to deliver on many of these promises. In reality, a case can be made for system replacement in the cloud that will keep all stakeholders’ compliance requirements, while setting up the organization to take advantage of powerful digital technologies and promote innovation and collaboration.
Join us as industry leaders Aaron Sato (Twist Bioscience), John Conway (20/15 Visoneers) and Loren Perelman (Benchling) discuss the case for digital transformation to fuel scientific innovation, what’s required to stay competitive in an evolving industry, and their approach to leveraging technology to future-proof biotech R&D.
John Conway is a global thought leader in R&D IT and Informatics Strategy and has spent over 30 years in R&D laboratories, scientific informatics, computational methods, and scientific software across Merck, GSK, and AstraZeneca. He founded 20/15 Visioneers in 2019 and works with large biopharma organizations and next-gen startups to evaluate their tech stack and drive digital transformation.
Aaron Sato, Ph.D., is a proven biologics leader adept at managing teams to discover and develop novel first-in-class antibody therapeutics. Prior to Twist Bioscience, he served as Chief Scientific Officer of LakePharma, which discovers novel antibody therapeutics for its clients. Prior to LakePharma, he oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He earned his Ph.D. from the Massachusetts Institute of Technology, and he is an author of over 30 peer-reviewed papers and 40 issued patents in the antibody space.
Loren Perelman is a Solutions Excellence Consultant at Benchling. His career has been focused on helping organizations make better use of their primary asset, data, by improving methods of collection and utilization. Prior to Benchling, Loren was Vice President of Scientific Solutions at Riffyn, working with various customers in the Biotech and Biopharma spaces. Before Riffyn, he spent over a decade leading R&D, Process Development, and Manufacturing teams in those same spaces, with a focus on quality, analytical chemistry, and stats/modeling. His education includes a Ph.D. in Materials Science from UCSD and a B.S. in Chemistry from Harvey Mudd College.